Role of Biomarkers In Neurodegenerative Diseases

Global Parkinson Disease Drug Biomarkers Insight 2028 Report Highlights:


  • Global Parkinson’s Disease Antibodies Market Opportunity: > USD 8 Billion
  • Parkinson’s Disease Clinical Trials Insight: > 300 Drugs In Trials
  • Parkinson’s Disease Biomarkers Sourced During Clinical Trials
  • Parkinson’s Disease Insight By Classification
  • Insight On  Biomarkers Sourced From Trials By Drugs & Indication
  • Biomarker Name & Function Insight By Drug
  • Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication


Download Report Sample:


Global Alzheimer's Disease Drug Biomarkers Insight 2028 Report Highlights:


  • Global Alzheimer's Disease Antibodies Market Opportunity: > USD 5 Billion
  • Alzheimer's Disease Clinical Trials Insight: > 200 Drugs In Trials
  • Alzheimer's Disease Biomarkers Sourced During Clinical Trials
  • Alzheimer's Disease Insight By Classification
  • Insight On  Biomarkers Sourced From Trials By Drugs & Indication
  • Biomarker Name & Function Insight By Drug
  • Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication


Download Report Sample:


With the increase in life expectancy in several countries, the prevalence of neurodegenerative diseases has considerable increased. Alzheimer disease is most commonly occurring neurodegenerative disease and accounts for 60–70% of all dementia cases. The affected individuals typically develop episodic memory impairment followed by other cognitive symptoms, including difficulties with language, difficulties with executive and visuospatial functions and, ultimately, dementia. Another, Parkinson disease is second most occurring neurodegenerative disorder which is characterized by the progressive loss of dopaminergic neurons.


The surge in prevalence of these diseases has poses a global threat to elderly population. The main reasons for this are lack of efficient therapy, which is mainly due to late diagnosis of the disease at advanced stage. To mitigate the challenges associated with early diagnosis, several research studies are ongoing to identify potential biomarkers. Biomarkers can assist in diagnosis, demonstrate target engagement, support disease modification, and monitor for safety.


The National Institute of Neurological Disorders and Stroke provides funding, such as development grants and cooperative agreements for researchers conducting studies related to biomarker discovery, analytical validation, and clinical validation. Thus, the presence of organizations offering funds at various stages of research is anticipated to drive market growth. For instance, the University of North Texas Health Science Center (HSC) was awarded around US$ 45.5 Million funds from the National Institutes of Health (NIH) to support research regarding health disparities in Alzheimer's and brain aging. NIH is offering additional funds for biomarkers research for the ongoing Health and Aging Brain Among Latino Elders (HABLE) study. These initiatives by government bodies are expected to drive the growth of market during the forecast period.


Recently, there has been shift in the approach of pharmaceutical companies. Both big pharmaceuticals and biotech companies have realized that these two sectors have more to gain from working together, than by competing. This has led to a flurry of deals being signed in the past few years between big pharma and big tech. For instance in 2022, Quanterix Corporation entered into collaboration with Eli Lilly to advance the diagnosis, monitoring and treatment of Alzheimer’s disease. As part of the collaboration, Quanterix will receive a non-exclusive, world-wide license to Lilly’s proprietary P-tau217 antibody technology for potential near-term use in research use only products and services, and future in vitro diagnostic applications. Further, Cerveau Technologies also announced research collaboration with Roche on the use of Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.


Further, Terran Biosciences has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio. This novel technology has already demonstrated promising clinical applications in several studies across a number of indications including schizophrenia, Parkinson's disease, Alzheimer's disease, major depression, drug addiction, and post-traumatic stress disorder (PTSD).


As per our report findings, the global neurodegenerative disease biomarkers are expected to surpass US$ 13 Billion by 2028. The key factors that boost the growth of market include  increase in focus on developing cost-effective biomarker testing and rise in demand for noninvasive diagnostic techniques for Alzheimer’s and Parkinson’s. In addition, surge in adoption of neurological biomarkers in clinical trials supplement the market growth. However, implementation of stringent government regulations towards the approval of commercial use of biomarkers and emerging ethical issues regarding early diagnosis of Alzheimer’s and Parkinson’s diseases are expected to hamper the market growth. Conversely, rise in demand for personalized medicine is anticipated to offer profitable opportunities for the expansion of the market.


Our report provides in-depth analysis on the currently available biomarker across various stages of clinical trial. This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges that will determine the market’s future growth. The major companies mentioned in the report are Amgen, Roche, Pfizer, Gilead Sciences, GlaxoSmthKline, and others.




Preeti Dureja

Research Partner

Biomarkers Insights




Back to news